Clinical Trial

Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies

Name: Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies — clinical trial record (NCT07364513)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Record status

This record was last updated January 23, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.

Summary

Open-Label Study (Phase Ib) of Type 1 Interferonopathy patients receiving IMSB301 monotherapy.

Trial Details

NCT Number	NCT07364513
Lead Sponsor	ImmuneSensor Therapeutics Inc.
Conditions	Type 1 Interferonopathies
Enrollment	6 participants
Start Date	2026-01-12
Primary Completion	2026-07-30 (estimated)
Study Completion	2026-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-23